Skip to content

Neuropace, Inc. NPCE Deferred Revenue

Deferred Revenue at other companies

LivaNova logo
LivaNovaLIVN
$16.2M+41.5%
ClearPoint Neuro logo
ClearPoint NeuroCLPT
$1.81M+12.1%
ARS Pharmaceuticals, Inc. logo
ARS Pharmaceuticals, Inc.SPRY
$757K+40.2%
Septerna, Inc. logo
Septerna, Inc.SEPN
$59.76M
ITG
Integer HoldingsITGR
$5.38M+32.5%
Medtronic logo
MedtronicMDT

Other financials

Income statement

See full
Revenue$22.1M-2.0%
Gross profit$18.0M+4.1%
Operating income-$5.6M-8.2%
Net income-$6.7M-1.5%
EPS (diluted)-$0.20+4.8%

Balance sheet

See full
Cash & equivalents$15.6M-42.4%
Total debt$70.5M-3.7%
Total equity$14.5M-40.4%
Total assets$98.9M-10.3%

Cash flow

See full
Operating cash flow-$5.9M+21.1%
CapEx$117.0K+216%
Free cash flow-$6.0M+20.0%

Valuation

See full
Market cap$557.77M+63.4%
Enterprise value$612.6M+58.1%
P/S5.6×+1.6×

Profitability

See full
Gross margin78.3%+3.5pp
Operating margin-16.8%-3.5pp
Net margin-21.7%-4.5pp
FCF margin-10.3%-3.5pp

Returns & leverage

See full
Return on equity-111.4%-13.1pp
Debt / equity4.9×+1.9×
Current ratio5.4×-1.2×

Where this comes from

Reported directly by Neuropace, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.

The official record: Neuropace, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Neuropace, Inc.'s deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Neuropace, Inc.'s deferred revenue?
Neuropace, Inc. (NPCE) reported deferred revenue of $126K in Q1 2026.
How has Neuropace, Inc.'s deferred revenue changed year-over-year?
Neuropace, Inc.'s deferred revenue decreased by 81.5% year-over-year, from $680K to $126K.
What does deferred revenue mean?
Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.